Advertisement

A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer

      Abstract

      This article reviews the available literature that describes the incidence, diagnosis, mechanism, symptoms, and management of pulmonary toxicity induced by radiation therapy and current systemic medications used to treat breast cancer. An extensive literature search was conducted via Ovid Medline to identify all potentially relevant articles written in English from 2010 through January 2020. Additional relevant articles outside the time frame were included as needed. Although the risk of pulmonary toxicity from various breast cancer treatments is small in most instances, it can be fatal. Due to the high prevalence of breast cancer and the range of treatment options, healthcare providers should be aware of the risk of pulmonary toxicity from those treatments and how to prevent or manage complications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • American Cancer Society
        Breast Cancer Facts & Figures 2019-2020.
        American Cancer Society, Inc, Atlanta2019
        • Willemsen AECAB
        • Tol J
        • van Erp NP
        • et al.
        Prospective study of drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus plus exemestane.
        Target Oncol. 2019; 14: 441-451
        • Segura A
        • Yuste A
        • Cercos A
        • et al.
        Pulmonary fibrosis induced by cyclophosphamide.
        Ann Pharmacother. 2001; 35: 894-897
        • Dang CT
        • D'Andrea GM
        • Moynahan ME
        • et al.
        Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
        Clin Cancer Res. 2004; 10: 5754-5761
        • Chap L
        • Shpiner R
        • Levine M
        • Norton L
        • Lill M
        • Glaspy J.
        Pulmonary toxicity of high-dose chemotherapy for breast cancer: A non-invasive approach to diagnosis and treatment.
        Bone Marrow Transplant. 1997; 20: 1063-1067
        • Antman K
        • Ayash L
        • Elias A
        • et al.
        High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
        J Natl Cancer Inst Monogr. 1994; : 91-94
        • Wilczynski SW
        • Erasmus JJ
        • Petros WP
        • Vredenburgh JJ
        • Folz RJ.
        Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer.
        Am J Respir Crit Care Med. 1998; 157: 565-573
        • Malik SW
        • Myers JL
        • DeRemee RA
        • Specks U.
        Lung toxicity associated with cyclophosphamide use: Two distinct patterns.
        Am J Respir Crit Care Med. 1996; 154: 1851-1856
        • Mylavarapu S
        • Das A
        • Roy M.
        Role of BRCA mutations in the modulation of response to platinum therapy.
        Fronti Oncol Front Media S.A. 2018; 8
        • Jacobs C
        • Slade M
        • Lavery B.
        Doxorubicin and boop. A possible near fatal association.
        Clin Oncol. 2002; 14 (Elsevier): 262
        • Mark M
        • Thürlimann B.
        Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
        Med Oncol. 2012; 29: 1477-1478
        • Mazzotta M
        • Giusti R
        • Iacono D
        • Lauro S
        • Marchetti P.
        Pulmonary fibrosis after pegylated liposomal doxorubicin in elderly patient with cutaneous angiosarcoma.
        Case Rep Oncol Med. 2016; 2016
        • Cortes J
        • O'Shaughnessy J
        • Loesch D
        • et al.
        Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
        Lancet. 2011; 377: 914-923
        • Swami U
        • Shah U
        • Goel S.
        Eribulin in cancer treatment.
        Marine Drugs. 2015; 13 (MDPI AG): 5016-5058
        • Nakamura K
        • Kato M
        • Miyashita Y
        • et al.
        Development of interstitial pneumonia during treatment with eribulin: a case report.
        BMC Res Notes. 2017; 10: 1-4
        • Takiar V
        • Strom EA
        • Baumann DP
        • Meric-Bernstam F
        • Alvarez RH
        • Gonzalez-Angulo AM.
        Locoregional Interaction of Ixabepilone (Ixempra) After Breast Cancer Radiation.
        Oncologist. 2013; 18: 265-270
        • Abal M
        • Andreu J
        • Taxanes BI
        Microtubule and centrosome targets, and cell cycle dependent mechanisms of action.
        Curr Cancer Drug Targets. 2005; 3: 193-203
        • Schmid P
        • Abraham J
        • Chan S
        • et al.
        AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind, placebo-controlled, phase II trial.
        J Clin Oncol. 2018; 36: 1007
        • Aigner J
        • Marme F
        • Smetanay K
        • Schuetz F
        • Jaeger D
        • Schneeweiss A.
        Nab-paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
        Anticancer Res. 2013; 33: 3407-3414
        • Bielopolski D
        • Evron E
        • Moreh-Rahav O
        • Landes M
        • Stemmer SM
        • Salamon F.
        Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.
        J Chemother. 2017; 29: 113-117
        • Vahid B
        • Marik PE.
        Pulmonary complications of novel antineoplastic agents for solid tumors.
        Chest. 2008; 133: 528-538
        • Kouroussis C
        • Mavroudis D
        • Kakolyris S
        • et al.
        High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: Results of a dose-finding study.
        Lung Cancer. 2004; 44: 363-368
        • Wang CJ
        • Chang HT
        • Chang CY.
        Docetaxel-related interstitial pneumonitis.
        Ther Clin Risk Manag. 2015; 11: 1813-1816
        • Njigha E
        • Vuky J
        • Paxton J
        • Alison P
        Use of nanoparticle albumin-bound paclitaxel in patients with breast cancer and paclitaxel-induced pneumonitis: single-center case series.
        J Hematol Oncol Pharm. 2019; 9: 199-205
        • Yasuda Y
        • Nomizo T
        • Ozasa H
        • et al.
        Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.
        Mol Clin Oncol. 2017; 7: 677-680
        • Gregory RK
        • Smith IE.
        Vinorelbine - A clinical review.
        Br J Cancer. 2000; 82 (Nature Publishing Group): 1907-1913
        • Ribeiro de Oliveira Santos MB
        • Mergulhão P.
        Vinorelbine-induced acute respiratory distress syndrome treated with non-invasive ventilation and immunosuppressive therapy.
        Respirol Case Rep. 2018; 6: e00349
        • Yanagitani N
        • Shimizu Y
        • Kara K
        • et al.
        Pulmonary toxicity associated with vinorelbine-based chemotherapy in breast cancer - PubMed.
        Gan To Kagaku Ryoho. 2008; 35: 1619-1621
        • Xie Z
        • Zhang Y
        • Jin C
        • Fu D.
        Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: A meta-analysis and literature review.
        Oncotarget. 2018; 9: 7148-7161
        • Binder D
        • Hübner RH
        • Temmesfeld-Wollbrück B
        • Schlattmann P.
        Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.
        Cancer Chemother Pharmacol. 2011; 68: 1575-1583
        • Antolín S
        • Calvo L
        • Dopico D
        • Quindós M
        • Reboredo M
        • Carral A.
        Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine.
        Clin Transl Oncol. 2010; 12: 450-452
        • Joerger M
        • Gunz A
        • Speich R
        • Pestalozzi BC.
        Gemcitabine-related pulmonary toxicity.
        Swiss Med Wkly. 2002; 132: 17-20
        • Sauer-Heilborn A
        • Kath R
        • Schneider CP
        • Höffken K.
        Severe non-haematological toxicity after treatment with gemcitabine.
        J Cancer Res Clin Oncol. 1999; 125: 637-640
        • Belknap SM
        • Kuzel TM
        • Yarnold PR
        • et al.
        Clinical features and correlates of gemcitabine-associated lung injury: Findings from the RADAR project.
        Cancer. 2006; 106: 2051-2057
        • Sherrod AM
        • Brufsky A
        • Puhalla S.
        A case of late-onset gemcitabine lung toxicity.
        Clin Med Insights Oncol. 2011; 5: 171-176
        • Boiselle PM
        • Morrin MM
        • Huberman MS.
        Gemcitabine pulmonary toxicity: CT features.
        J Comput Assist Tomogr. 2000; 24: 977-980
        • Masuda N
        • Lee S-J
        • Ohtani S
        • et al.
        Adjuvant capecitabine for breast cancer after preoperative chemotherapy.
        N Engl J Med. 2017; 376: 2147-2159
      1. Benthin CJ, Allada G. Capecitabine-induced lung injury.

        • Chan AK
        • Choo BA
        • Glaholm J.
        Pulmonary toxicity with oxaliplatin and capecitabine/5-fluorouracil chemotherapy: a case report and review of the literature.
        Onkologie. 2011; 34: 443-446
        • Kadakia A
        • Rajan SS
        • Abughosh S
        • Du XL
        • Johnson ML.
        CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer.
        Am J Clin Oncol Cancer Clin Trials. 2015; (Lippincott Williams and Wilkins): 165-173
        • Jakubovic BD
        • Donovan A
        • Webster PM
        • Shear NH.
        Methotrexate-induced pulmonary toxicity.
        Can Respir J. 2013; 20527912https://doi.org/10.1155/2013/527912
        • Gajria D
        • Chandarlapaty S.
        HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies.
        Expert Rev Anticancer Therapy. 2011; 11 (NIH Public Access): 263-275
        • Dillman RO.
        Perceptions of herceptin®: a monoclonal antibody for the treatment of breast cancer.
        Cancer Biother Radiopharm. 1999; 14: 5-10
        • Piccart-Gebhart MJ
        • Procter M
        • Leyland-Jones B
        • et al.
        Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
        N Engl J Med. 2005; 353: 1659-1672
        • von Minckwitz G
        • Huang C-S
        • Mano MS
        • et al.
        Trastuzumab emtansine for residual invasive HER2-positive breast cancer.
        N Engl J Med. 2019; 380: 617-628
        • Von Minckwitz G
        • Procter M
        • De Azambuja E
        • et al.
        Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer.
        N Engl J Med. 2017; 377: 122-131
        • Martin M
        • Holmes FA
        • Ejlertsen B
        • et al.
        Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1688-1700
        • Modi S
        • Saura C
        • Yamashita T
        • et al.
        Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.
        N Engl J Med. 2019; ([Accessed: January 1, 2020]Available from)
      2. Herceptin (trastuzumab) label [Internet]. [cited Accessed: April 18, 2020]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.

        • Sugaya A
        • Ishiguro S
        • Mitsuhashi S
        • et al.
        Interstitial lung disease associated with trastuzumab monotherapy: a report of 3 cases.
        Mol Clin Oncol. 2017; 6: 229-232
        • Chaudhuri T
        • Karmakar S.
        Trastuzumab-induced pulmonaryfibrosis: a case report and review of literature.
        Clin Cancer Investig J. 2012; 1: 242
        • Vahid B
        • Mehrotra A.
        Trastuzumab (Herceptin)-associated lung injury.
        Respirology. 2006; 11: 655-658
        • Pepels MJ
        • Boomars KA
        • Van Kimmenade R
        • Hupperets PS.
        Life-threatening interstitial lung disease associated with trastuzumab: case report.
        Breast Cancer Res Treat. 2009; 113: 609-612
        • Swain SM
        • Baselga J
        • Kim S-B
        • et al.
        Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
        N Engl J Med. 2015; 372: 724-734
        • Egloff H
        • Kidwell KM
        • Schott A.
        Ado-trastuzumab emtansine-induced pulmonary toxicity: a single-institution retrospective review.
        Case Rep in Oncology. 2018; 11 (S. Karger AG): 527-533
        • Modi S
        • Saura C
        • Yamashita T
        • et al.
        Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.
        N Engl J Med. 2020; 382: 610-621
      3. Powell CA, Ross D, Gemma A, et al. Characterization, monitoring, and management of interstitial lung disease in patients with metastatic breast cancer: analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload. Poster presented at: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, TX. Vol. 18.

      4. ENHERTU® (fam-trastuzumab deruxtecan-nxki) label [Internet]. [Accessed: April 18 2020]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf.

        • Opdam FL
        • Guchelaar H
        • Beijnen JH
        • Schellens JHM.
        Lapatinib for advanced or metastatic breast cancer.
        Oncologist. 2012; 17: 536-542
        • Capri G
        • Chang J
        • Chen S-C
        • et al.
        An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
        Ann Onco. 2010; 21: 474-480https://doi.org/10.1093/annonc/mdp373
        • Yamamoto D
        • Yamamoto C
        • Yamamoto M.
        [A case of interstitial pneumonitis induced by Lapatinib plus Letrozole].
        Gan To Kagaku Ryoho. 2016 Nov; 43: 2059-2061
        • Xu ZQ
        • Zhang Y
        • Li N
        • et al.
        Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
        BMJ Open. 2017; 7 (BMJ Publishing Group)
        • Vahid B
        • Esmaili A.
        Erlotinib-associated acute pneumonitis: Report of two cases.
        Can Respir J. 2007; 14: 167
        • Scott SC
        • Lee SS
        • Abraham J.
        Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
        Sem Oncol. 2017; 44 (W.B. Saunders): 385-394
        • Finn RS
        • Dering J
        • Conklin D
        • et al.
        PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
        Breast Cancer Res. 2009; 11: R77
        • Finn RS
        • Martin M
        • Rugo HS
        • et al.
        Palbociclib and letrozole in advanced breast cancer.
        N Engl J Med. 2016; 375: 1925-1936
        • Slamon DJ
        • Neven P
        • Chia S
        • et al.
        Phase III Randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3.
        J Clin Oncol. 2018; 36: 2465-2472
      5. FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer | FDA [Internet]. [Accessed: April 19 2020]. Available from: https://www.fda.gov/drugs/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer.

        • Jazieh KA
        • Budd GT
        • Dalpiaz N
        • Abraham J.
        Can CDK4/6 inhibitors cause fatal lung injury?.
        Expert Rev Anticancer Ther. 2019; 19: 917-919
        • Piccart M
        • Hortobagyi GN
        • Campone M
        • et al.
        Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.
        Ann Oncol. 2014; 25: 2357-2362https://doi.org/10.1093/annonc/mdu456
        • Duran I
        • Goebell PJ
        • Papazisis K
        • et al.
        Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
        Expert Opin Drug Saf. 2014; 13: 361-372
        • Willemsen AECAB
        • Grutters JC
        • Gerritsen WR
        • van Erp NP
        • van Herpen CML
        • Tol J.
        mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
        Int J Cancer. 2016; 138: 2312-2321
        • André F
        • Ciruelos E
        • Rubovszky G
        • et al.
        Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer.
        N Engl J Med. 2019; 380: 1929-1940
        • Fruman DA
        • Chiu H
        • Hopkins BD
        • Bagrodia S
        • Cantley LC
        • Abraham RT.
        The PI3K pathway in human disease.
        Cell. 2017; 170 (Cell Press): 605-635
      6. PIQRAY® (alpelisib) FDA Label [Internet]. [Accessed: April 19 2020]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf.

        • Pujade-Lauraine E
        • Ledermann JA
        • Selle F
        • et al.
        Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1274-1284
        • Robson M
        • Im SA
        • Senkus E
        • et al.
        Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.
        N Engl J Med. 2017; 377: 523-533
        • Litton JK
        • Rugo HS
        • Ettl J
        • et al.
        Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation.
        N Engl J Med. 2018; 379: 753-763
      7. Tanner Ringley J, Moore DC, Patel J, Rose MS. Poly (ADP-ribose) polymerase inhibitors in the management of Ovarian cancer: a drug class review. Vol. 43, P and T. Medi Media USA Inc; 2018. p. 549–56.

        • Bardia A
        • Mayer IA
        • Vahdat LT
        • et al.
        Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer.
        N Engl J Med. 2019; 380: 741-751
        • Madarnas Y
        • Webster P
        • Shorter AM
        • Bjarnason GA.
        Irinotecan-associated pulmonary toxicity.
        Anticancer Drugs. 2000; 11: 709-713
        • Michielin O
        • Udry E
        • Périard D
        • Matzinger O
        • Lobrinus JA
        • Stupp R.
        Irinotecan-induced interstitial pneumonia.
        Lancet Oncol. 2004; 5: 322-324
        • Solinas C
        • Gombos A
        • Latifyan S
        • Piccart-Gebhart M
        • Kok M
        • Buisseret L.
        Targeting immune checkpoints in breast cancer: an update of early results.
        ESMO Open. 2017; 2e000255
        • Schmid P
        • Adams S
        • Rugo HS
        • et al.
        Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.
        N Engl J Med. 2018; 379: 2108-2121
        • Schmid P
        • Cortes J
        • Pusztai L
        • et al.
        Pembrolizumab for early triple-negative breast cancer.
        N Engl J Med. 2020; 382: 810-821
        • Thompson JA
        • Schneider BJ
        • Brahmer J
        • et al.
        NCCN guidelines insights: m otherapy-related toxicities, version 1.2020.
        J Natl Compr Canc Netw. 2020; 18
        • Cui P
        • Liu Z
        • Wang G
        • et al.
        Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study.
        Cancer Med. 2018; 7: 4115-4120
        • Leger P
        • Limper AH
        • Maldonado F.
        Pulmonary toxicities from conventional chemotherapy.
        Clin Chest Med. 2017; 38 (W.B. Saunders): 209-222
        • Omarini C
        • Thanopoulou E
        • Johnston SRD.
        Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.
        Breast Cancer Rese Treatment. 2014; 146 (Springer New York LLC): 245-258
        • Iacovelli R
        • Palazzo A
        • Mezi S
        • Morano F
        • Naso G
        • Cortesi E.
        Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
        Acta Oncol (Madr). 2012; 51: 873-879
        • Alkan A.
        Interstitial pneumonitis associated with trastuzumab emtansine.
        J Oncol Pharm Pract. 2019; 25: 1798-1800
        • Peddi PF
        • Shatsky RA
        • Hurvitz SA.
        Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
        Cancer Treat Rev. 2014; 40: 320-326
        • Sakai F
        • Johkoh T
        • Kusumoto M
        • Arakawa H
        • Takahashi M.
        Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.
        Int J Clin Oncol. 2012; 17: 542-550
      8. Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. 2017 [Accessed: June 24 2020]. Available at: https://www.meddra.org/.

        • Brahmer JR
        • Lacchetti C
        • Schneider BJ
        • et al.
        Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.
        J Clin Oncol. 2018; 36: 1714-1768
        • Kubo K
        • Azuma A
        • Kanazawa M
        • et al.
        Consensus statement for the diagnosis and treatment of drug-induced lung injuries [Internet].
        Respir Investig. 2013; 51: 260-277
        • Darby S
        • McGale P
        • Correa C
        • et al.
        Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials.
        Lancet. 2011; 378: 1707-1716
        • Darby SC
        • McGale P
        • Taylor CW
        • Peto R.
        Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries.
        Lancet Oncol. 2005; 6: 557-565
        • Kwa SLS
        • Lebesque J V
        • Theuws JCM
        • et al.
        Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients.
        Int J Radiat Oncol Biol Phys. 1998; 42: 1-9
        • Warren LEG
        • Miller CL
        • Horick N
        • et al.
        The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: A prospective cohort study.
        Int J Radiat Oncol Biol Phys. 2014; 88: 565-571
        • Huang Y
        • Zhang W
        • Yu F
        • Gao F.
        The cellular and molecular mechanism of radiation-induced lung injury.
        Med Sci Monitor. 2017; 23 (International Scientific Information, Inc.): 3446-3450
        • Rodrigues G
        • Lock M
        • D'Souza D
        • Yu E
        • Van Dyk J
        Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer - A systematic review.
        Radiother Oncol. 71. 2004: 127-138
        • Jeba J
        • Isiah R
        • Subhashini J
        • Backianathan S
        • Thangakunam B
        • Christopher DJ.
        Radiation pneumonitis after conventional radiotherapy for breast cancer: a prospective study.
        J Clin Diagn Res. 2015; 9: XC01-XC05
        • Blomqvist C
        • Tiusanen K
        • Elomaa I
        • et al.
        The combination of radiotherapy, adjuvant chemotherapy (Cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage ii breast cancer. long-term follow-up results of a randomised trial.
        Br J Cancer. 1992; 66: 1171-1176
        • Brackstone M
        • Palma D
        • Tuck AB
        • et al.
        Concurrent neoadjuvant chemotherapy and radiation therapy in locally advanced breast cancer.
        Int J Radiat Oncol Biol Phys. 2017; 99: 769-776
        • Tsoutsou PG
        • Koukourakis MI.
        Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research.
        Int J Radiat Oncol Biol Phys. 2006; 66: 1281-1293
        • Vogelius IR
        • Bentzen SM.
        A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.
        Acta Oncol. 2012; 51: 975-983
        • Palma DA
        • Senan S
        • Tsujino K
        • et al.
        Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
        Int J Radiat Oncol Biol Phys. 2013; 85: 444-450
        • Tajvidi M
        • Sirous M
        • Sirous R
        • Hajian P.
        Partial frequency of radiation pneumonitis and its association with the energy and treatment technique in patients with breast cancer, Isfahan, Iran.
        J Res Med Sci. 2013; 18: 413-416
        • Lingos TI
        • Recht A
        • Vicini F
        • Abner A
        • Silver B
        • Harris JR.
        Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy.
        Int J Radiat Oncol Biol Phys. 1991; 21: 355-360
        • Taghian AG
        • Assaad SI
        • Niemierko A
        • et al.
        Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
        J Natl Cancer Inst. 2001; 93: 1806-1811
        • Giridhar P
        • Mallick S
        • Rath GK
        • Julka PK.
        Radiation induced lung injury: prediction, assessment and management.
        Asian Pac J Cancer Prevent. 2015; 16: 2613-2617
        • Brownlee Z
        • Garg R
        • Listo M
        • Zavitsanos P
        • Wazer DE
        • Huber KE.
        Late complications of radiation therapy for breast cancer: evolution in techniques and risk over time.
        Gland Surg. 2018; 7 (AME Publishing Company): 371-378
        • Smith BD
        • Bellon JR
        • Blitzblau R
        • et al.
        Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.
        Pract Radiat Oncol. 2018; 8: 145-152
        • Bradley J
        • Movsas B.
        Radiation pneumonitis and esophagitis in thoracic irradiation.
        Cancer Treat Res. 2006; 128: 43-64
        • Gao F
        • Fish BL
        • Moulder JE
        • Jacobs ER
        • Medhora M.
        Enalapril mitigates radiation-induced pneumonitis and pulmonary fibrosis if started 35 days after whole-thorax irradiation.
        Radiat Res. 2013; 180: 546-552
        • Molteni A
        • Moulder JE
        • Cohen EF
        • et al.
        Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker.
        Int J Radiat Biol. 2000; : 523-532
        • Osterreicher J
        • Mokry J
        • Navrátil L
        • et al.
        The alveolar septal thickness and type II pneumocytes number in irradiated lungs, time expression and the effect of pentoxifylline.
        Acta medica (Hradec Kral [Internet]. 2001; 44: 15-19
        • Jain V
        • Berman AT.
        Radiation pneumonitis: old problem, new tricks.
        Cancers. 2018; 10 (MDPI AG): 1-16
        • Glassman L
        • Awan O
        • Betancourt J
        Kadcyla-induced lung toxicity years after adjuvant therapy with trastuzumab in a patient with metastatic breast cancer.
        Chest. 2018; 154: 427Ahttps://doi.org/10.1016/j.chest.2018.08.389
        • Ofer L
        • Ekaterina P
        • Yitzhak S
        • et al.
        Fatal palbocyclib-related interstitial pneumonitis.
        Arch Clin Med Case Rep. 2019; 3: 162-166
        • Hui R
        • Pearson A
        • Cortés J
        • et al.
        Lucitanib for the treatment of HR+/HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study.
        Clin Cancer Res. 2019; (Available from)